Literature DB >> 17360990

Loss of vaccine-induced immunity to varicella over time.

Sandra S Chaves1, Paul Gargiullo, John X Zhang, Rachel Civen, Dalya Guris, Laurene Mascola, Jane F Seward.   

Abstract

BACKGROUND: The introduction of universal varicella vaccination in 1995 has substantially reduced varicella-related morbidity and mortality in the United States. However, it remains unclear whether vaccine-induced immunity wanes over time, a condition that may result in increased susceptibility later in life, when the risk of serious complications may be greater than in childhood.
METHODS: We examined 10 years (1995 to 2004) of active surveillance data from a sentinel population of 350,000 subjects to determine whether the severity and incidence of breakthrough varicella (with an onset of rash >42 days after vaccination) increased with the time since vaccination. We used multivariate logistic regression to adjust for the year of disease onset (calendar year) and the subject's age at both disease onset and vaccination.
RESULTS: A total of 11,356 subjects were reported to have varicella during the surveillance period, of whom 1080 (9.5%) had breakthrough disease. Children between the ages of 8 and 12 years who had been vaccinated at least 5 years previously were significantly more likely to have moderate or severe disease than were those who had been vaccinated less than 5 years previously (risk ratio, 2.6; 95% confidence interval [CI], 1.2 to 5.8). The annual rate of breakthrough varicella significantly increased with the time since vaccination, from 1.6 cases per 1000 person-years (95% CI, 1.2 to 2.0) within 1 year after vaccination to 9.0 per 1000 person-years (95% CI, 6.9 to 11.7) at 5 years and 58.2 per 1000 person-years (95% CI, 36.0 to 94.0) at 9 years.
CONCLUSIONS: A second dose of varicella vaccine, now recommended for all children, could improve protection from both primary vaccine failure and waning vaccine-induced immunity. Copyright 2007 Massachusetts Medical Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360990     DOI: 10.1056/NEJMoa064040

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  85 in total

Review 1.  Immune modulation during latent herpesvirus infection.

Authors:  Douglas W White; R Suzanne Beard; Erik S Barton
Journal:  Immunol Rev       Date:  2012-01       Impact factor: 12.988

2.  A varicella outbreak in a school with high one-dose vaccination coverage, Beijing, China.

Authors:  Li Lu; Luodan Suo; Juan Li; Lijun Zhai; Qingxiu Zheng; Xinghuo Pang; Stephanie R Bialek; Chengbin Wang
Journal:  Vaccine       Date:  2012-06-09       Impact factor: 3.641

3.  Humoral and cellular immune responses to measles and tetanus: the importance of elapsed time since last exposure and the nature of the antigen.

Authors:  Patricia O Viana; Erika Ono; Maristela Miyamoto; Reinaldo Salomao; Beatriz T Costa-Carvalho; Lily Y Weckx; Maria Isabel de Moraes-Pinto
Journal:  J Clin Immunol       Date:  2010-04-20       Impact factor: 8.317

4.  Effectiveness of 2 doses of varicella vaccine in children.

Authors:  Eugene D Shapiro; Marietta Vazquez; Daina Esposito; Nancy Holabird; Sharon P Steinberg; James Dziura; Philip S LaRussa; Anne A Gershon
Journal:  J Infect Dis       Date:  2011-02-01       Impact factor: 5.226

5.  Fifteen years of routine childhood varicella vaccination in the United States-strong decrease in the burden of varicella disease and no negative effects on the population level thus far.

Authors:  Andrea Streng; Johannes G Liese
Journal:  Transl Pediatr       Date:  2014-10

6.  Influence of age and nature of primary infection on varicella-zoster virus-specific cell-mediated immune responses.

Authors:  Adriana Weinberg; Ann A Lazar; Gary O Zerbe; Anthony R Hayward; Ivan S F Chan; Rupert Vessey; Jeffrey L Silber; Rob R MacGregor; Kenny Chan; Anne A Gershon; Myron J Levin
Journal:  J Infect Dis       Date:  2010-04-01       Impact factor: 5.226

7.  Human papillomavirus, vaccines and women's health: questions and cautions.

Authors:  Abby Lippman; Ryan Melnychuk; Carolyn Shimmin; Madeline Boscoe
Journal:  CMAJ       Date:  2007-08-01       Impact factor: 8.262

Review 8.  Should the UK introduce varicella vaccine?

Authors:  Marion Roderick; Athimalaipet V Ramanan; Adam Finn
Journal:  Arch Dis Child       Date:  2007-11-08       Impact factor: 3.791

9.  The HPV vaccine: an analysis of the FUTURE II study.

Authors:  Michelle Howard; Alice Lytwyn
Journal:  Can Fam Physician       Date:  2007-12       Impact factor: 3.275

Review 10.  Pathogenesis and current approaches to control of varicella-zoster virus infections.

Authors:  Anne A Gershon; Michael D Gershon
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.